In the last few years, new agents and procedures have received attention in the therapy of myelofibrosis with myeloid metaplasia (MMM). Vitamin D3 inhibits clonal proliferation and produces a monocytoid differentiation decreasing the synthesis of collagen. However, the clinical results are scanty and unpredictable. Recombinant interferons may be considered an effective cytoreductive drug to be used with the aim of avoiding the leukaemogenic effects of traditional chemotherapeutic agents, like hydroxyurea and busulphan. Few cases responded to recombinant erythropoietin, but a larger number of cases is needed to evaluate its clinical efficacy and the incidence of adverse events. Two case reports demonstrate that bone marrow transplantation is the only way to achieve a cure in MMM. It is now possible to place the new therapeutic options in a problem-oriented approach to the therapy of the disease.
|Number of pages||11|
|Journal||FORUM - Trends in Experimental and Clinical Medicine|
|Publication status||Published - 1993|
- myeloid metaplasia
- myeloproliferative disorders
ASJC Scopus subject areas